Mini Review
Volume 9 Issue 3 - 2021
Coronavirus (COVID-19), Origin, Infectivity, Epidemics, Therapeutics and Global Impacts
Da-Yong Lu1*, Jin-Yu Che1, Ting-Ren Lu2 and Hong-Ying Wu2*
1School of Life Sciences, Shanghai University, China
2College of Science, Shanghai University, China
*Corresponding Author: Da-Yong Lu, School of Life Sciences, Shanghai University, China.
Received: January 22, 2021; Published: February 27, 2021


The coronavirus (COVID-19) outbreaks and pandemic is growing rapidly in the past one year. In the past one year, total number of the infectious people is over one hundred million globally. It means we are still battling against viral epidemic spreading and therapeutic benefiting. The origin and pandemic of COVID-19 raised our concern greatly. To speed up global efforts against COVID-19, some evidence and association are noticed and discussed in the following. Collectively, epidemic condition, countrywide lockdown, therapeutic validity and preventive policy are addressed respectively. These patterns of medical experience can be introduced for facilitating and enhancing a possibility of futuristic guidance in new clinical scenarios.


Keywords: Infectious Disease; COVID-19; Viral Treatment; Viral Origin; Herbal Medicine; Drug Development; Viral Vaccines; Clinical Trial


    1. Zhu N., et al. “A novel coronavirus from patients with pneumonia in China”. The New England Journal of Medicine 8 (2020): 727-733.
    2. Ciotti M., et al. “COVID-19 outbreak: An overview”. Chemotherapy (2020).
    3. Miranda P and Getty AFP. “Coronavirus pandemic, nature’s pledge to you”. Nature 579 (2020): 471-472.
    4. Nowogrodzki A. “Cull, release or bring them home: coronavirus crisis forces hard decisions for labs with animals”. Nature 202 (2020): 580.
    5. Ledford H. “Coronavirus shuts down trials of drugs for multiple other diseases”. Nature 580 (2020): 15-16.
    6. Larson HJ. “Blocking information on COVID-19 can fuel the spread of misinformation”. Nature 580 (2020): 306.
    7. Lu DY., et al. “Future perspectives for controlling Ebola epidemics”. Metabolomics2 (2015): e135.
    8. Lu DY., et al. “The origins of HIV”. Advances in Pharmacoepidemiology and Drug Safety4 (2015): e136.
    9. Lu DY., et al. “The origins of HIV: A promising medical topic”. HIV: Current Therapeutic Research 2 (2016): 116.
    10. McMichael A and Hanke T. “HIV vaccines 1983-2003”. Nature Medicine 9 (2003): 874-880.
    11. Letvin N. “Moving forward in HIV vaccine development”. Science 326 (2009): 1196-1198.
    12. Korber B and Gnanakaran S. “Converging on an HIV vaccine”. Science 333 (2011): 1589-1590.
    13. Lu DY., et al. “HIV vaccination, is breakthrough underway?” Reviews on Recent Clinical Trials 2 (2016): 145-151.
    14. Burton DR and Weiss RA. “A boost for HIV vaccine design”. Science 329 (2010): 770-773.
    15. Lu DY., et al. “HIV vaccine for prevention and cure, a mission possible”. Reviews on Recent Clinical Trials 4 (2016): 290-296.
    16. Callaway E. “Should scientists infect healthy people with the coronavirus to test vaccines?” Nature (2020): 580.
    17. Callaway E. “Coronavirus vaccines five key question as trial begin”. Nature 578 (2020): 481.
    18. Ledford H. “How does COVID-19 kill? Uncertainty is hampering doctor’s ability to choose treatment”. Nature 580 (2020): 311-312.
    19. Lu DY., et al. “Treatment of influenza virus infections with Chinese medicine” Advances in Pharmacoepidemiology and Drug Safety Journal 1 (2012): e104.
    20. Parasuraman S. “Herbal drug discovery: challenges and perspectives”. Current Pharmacogenetics Personalized Medicine 1 (2018): 63-68.
    21. Maxmen A. “How blood from coronavirus survivors might save lives”. Nature 580 (2020): 16-17.
    22. Meade HM and Cavacini L. “The use of antibodies in treating hiv infection and suppressing hiv transmission”. WO2014040024 A1 (2014).
    23. Zhao Q., et al. “Recent developments on coronavirus main protease/3C like protease inhibitors”. Recent Patent Anti-infective Drug Discovery2 (2013): 150-156.
    24. Liu W., et al. “Effective chemicals against novel coronavirus (COVID-19) in China”. Current Topics in Medicinal Chemistry8 (2020): 603-605.
    25. Blaising J., et al. “Arbidolas as a broad-spectrum antiviral: an update”. Antiviral Research 107 (2014): 84-94.
    26. Vincent MJ., et al. “Chloroquine is a potent inhibitor of SARS coronavirus infection and spread”. Virology Journal 1 (2005): 69.
    27. Pattanayak S. “Alternative to antibiotics from herbal origin-outline of a comprehensive research project”. Current Pharmacogenomics Personalized Medicine1 (2018): 9-62.
    28. Lu DY and Lu TR. “Herbal medicine in new era”. Hospice and Palliative Medicine International Journal 4 (2019): 125-130.
    29. Lu DY and Lu TR. “Drug discoveries from natural resources”. Journal of Primary Health Care and General Practice 1 (2019): 28.
    30. Putta S., et al. “Possible role as multitarget therapeutic agents for prevention and therapy of chronic diseases”. Current Pharmaceutical Design 30 (2017): 4475-4483.
    31. Lu DY., et al. “Discover natural chemical drugs in modern medicines”. Metabolomics3 (2016): 181.
    32. Mathaiyan M., et al. “Binding property of HIVp 24 and reverse transcriptase by chocones from Pongamia pinnata seeds”. Bioinformatics6 (2018): 279-284.
    33. Palerson RR. “Corolyceps-a traditional Chinese medicine and another fungal therapeutic biofactory?” Phytochemistry 69 (2008): 1469-1495.
    34. Chen PX., et al. “Properties of Cordyceps Sinensis: A review”. The Journal of Functional Foods 1 (2015): 550-569.
    35. Van Der Klaauw AA and Farooqi IS. “The hunger genes: pathways to obesity”. Cell 161 (2015): 119-132.
    36. Lu DY., et al. “Obesity, risks and managements”. Metabolomics1 (2018): e155.
    37. Lu DY., et al. “An overview of obesity”. Metabolomics2 (2018): 200.
    38. Brestoff JJR and Artis D. “Immune regulation of metabolic homeostasis in health and disease”. Cell 161 (2015): 146-160.
    39. Lu DY., et al. “Human obesity, pathological and therapeutic advances”. EC Pharmacology and Toxicology4 (2019): 231-238.
    40. Lu DY., et al. “Pathology and treatments of obesity”. Trends in Medicine5 (2018): 157.
    41. Lu DY., et al. “Type 2 diabetes study, introduction and perspective”. The Open Diabetes Journal 8 (2018): 13-21.
    42. Lu DY., et al. “Type 2 diabetes treatment and drug development study”. The Open Diabetes Journal (2018): 8.
    43. Schroder ARW., et al. “HIV-1 integration in the human genome favors active genes and local hotspots”. Cell 110 (2002): 521-529.
    44. Lu DY and Ding J. “Sequencing the whole genome of infected human cells obtained from diseased patients-a proposed strategy for understanding and overcoming AIDS or other deadest virus-infected diseases”. Medical Hypotheses 68 (2007): 826-827.
    45. Smith AE and Helenius A. “How viruses enter animal cells”. Science 304 (2004): 237-242.
    46. Taha H., et al. “Parenteral patent drug S/GSK 1265744 has the potential to be an effective agent in pre-exposure prophylaxis against HIV infection”. Recent Patents on Anti-Infective Drug Discovery3 (2013): 213-218.
    47. Huang W and Petropoulos CJ. “Methods and compositions for determining virus susceptibility to integrase inhibitors”. EP2678453 A1 (2014).
    48. Lu DY., et al. “Keep up the pace of drug development evolution and expenditure”. Cancer Treatment Reviews 5 (2018): 165.
    49. De Wilde AH., et al. “Host factors in coronavirus replication”. Current Topics in Microbiology and Immunology 419 (2018): 1-42.
    50. Viana JDO., et al. “Drug discovery and computational strategies in the multitarget drugs era”. The Brazilian Journal of Pharmaceutical Sciences 54 (2018): e01010.
    51. Scotti L., et al. “In-silico analyses of natural products on Leishmania enzyme targets”. Mini-Reviews in Medicinal Chemistry 3 (2015): 253-269.
    52. Morris GM., et al. “Automated Docking using a Lamarckian genetic algorithm and empirical binding free energy functioning”. Journal of Computational Chemistry 19 (1998): 1639-1662.
    53. Lu DY., et al. “Anticancer drug combination, how far we can go through?” Anti-Cancer Agents in Medicinal Chemistry 1 (2017): 21-28.
    54. Lu DY., et al. “Drug combination in clinical cancer treatment”. Reviews on Recent Clinical Trials3 (2017): 202-211.
    55. Lu DY., et al. “HAART in HIV/AIDS treatments, future trends”. Infectious Disorders-Drug Targets1 (2018): 15-22.
Citation: Da-Yong Lu., et al. “Coronavirus (COVID-19), Origin, Infectivity, Epidemics, Therapeutics and Global Impacts”. EC Pharmacology and Toxicology 9.3 (2021): 100-107.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

May Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the May issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before May 21, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to